From Lab Breakthrough to Early Field Execution
Mubadala Capital’s Brazilian energy arm has framed the macauba palm as a long-term feedstock play rather than a short-term volume fix. According to company statements compiled by sector outlets, Acelen Renováveis plans to invest about US$3 billion to build an integrated biofuels chain anchored in macauba oil, with cultivation centred in Minas Gerais and an industrial hub in Bahia. The project aims to plant up to 144,000 hectares of macauba on degraded pastureland — an area slightly larger than Los Angeles — in what would be one of the world’s largest dedicated SAF feedstock programmes.
Acelen’s Agripark in Montes Claros, in northern Minas Gerais, has become the project’s technical fulcrum. Company reports cited by specialist media indicate that agronomists and biotechnicians have pushed macauba germination rates from the 3%–5% seen in nature to above 80%, using seed treatment and controlled nursery conditions. This shift turns a previously marginal native species into a plausible plantation crop and reduces the risk that field expansion stalls for biological reasons.
Meanwhile, Acelen has begun to move beyond experimentation. Brazil-focused outlets report that the company has acquired around 3,000 hectares as part of an agricultural rollout that targets up to 144,000 hectares over time. Management describes an approach built around hubs of 30,000–50,000 hectares, each with nearby crushing facilities, to shorten logistics chains and anchor local supply ecosystems. As a result, the early-stage footprint is small in absolute terms but signals a shift from proof-of-concept to structured deployment.
What Does the Bahia Biorefinery Mean for Investors?
The industrial spine of the project is a new biorefinery in Bahia, adjacent to Acelen’s existing Mataripe refinery in São Francisco do Conde. According to Brazil Stock Guide and other market commentators, the plant is designed to process about 20,000 barrels per day of renewable feedstock and produce roughly 1 billion litres per year of sustainable aviation fuel and hydrotreated vegetable oil — a drop-in renewable diesel. Company guidance points to start-up at the end of the decade, with full macauba-based output expected once plantations reach maturity around 2030.
Financing has also moved into place. Industry reports indicate that around US$1.5 billion of the capex tied to the Bahia biorefinery has been structured with a 12-lender consortium led by IFC and HSBC, with participation from BNDES (Brazil’s national development bank), IDB Invest and commercial banks including Bradesco and Bank of China. This mix signals a blend of development finance and private capital, and gives Acelen a lower-cost funding base than many pure-play biofuels start-ups.
However, macauba is a long-cycle tree crop, so the new refinery cannot initially rely on its own palm oil. To bridge that gap, Acelen has struck supply deals for alternative feedstocks. According to regional business media, Trafigura will provide about 470,000 tonnes per year of used cooking oil, with part of the resulting SAF volumes marketed into Europe and the United States. In parallel, a five-year contract with Bunge covers around 300,000 tonnes per year of certified soybean oil from Brazil and Argentina starting in 2029, totalling 1.5 million tonnes. These agreements help ensure early throughput and revenue even before macauba plantations reach scale.
Financing, Feedstock Risk and Investor Signals
For investors, the project’s appeal lies less in immediate returns and more in optionality on a constrained global SAF market. As one Latin America energy analyst put it, Acelen’s macauba strategy is an early-scale attempt to turn a native tree into a structured SAF asset class rather than a boutique story. If the agronomy holds and policy support for low-carbon aviation intensifies, the Bahia biorefinery could anchor a broader network of plants, with feedstock cost and security as key differentiators.
The project also fits neatly into Brazil’s broader bioenergy ambitions. The country has long positioned itself as a biofuels leader, and a large-scale SAF programme built on native species adds a new dimension to that narrative. For context, Brazil’s earlier biofuel success with sugarcane ethanol took decades to reach commercial scale — macauba proponents argue the timeline this time is shorter, given advances in agronomy and refining technology. Those watching Brazil’s emerging energy transition may also find relevant context in this analysis of Brazil-Egypt biofuels and BRICS trade opportunities, which outlines the international appetite for Brazilian low-carbon fuels.
The next signals to watch will be the pace of land acquisition, the performance of the first macauba plantings in Minas Gerais, and any firm offtake commitments from airlines or fuel distributors as Brazil’s SAF policy framework evolves.
Quick answers
Acelen Renováveis plans to invest approximately US$3 billion to build an integrated biofuels chain anchored in macauba oil, with cultivation in Minas Gerais and a biorefinery in Bahia targeting around 1 billion litres per year of SAF and renewable diesel.
Around US$1.5 billion of the biorefinery’s capex has been structured with a 12-lender consortium led by IFC and HSBC, with participation from BNDES, IDB Invest, Bradesco, and Bank of China.
To bridge the gap before macauba reaches scale around 2030, Acelen has secured a deal with Trafigura for 470,000 tonnes per year of used cooking oil and a five-year contract with Bunge for around 300,000 tonnes per year of certified soybean oil starting in 2029.









